{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:28:04Z","timestamp":1785472084714,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.ajkd.2022.10.016","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T20:19:31Z","timestamp":1671221971000},"page":"517-527.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2\/3 Randomized Clinical Trial"],"prefix":"10.1053","volume":"81","author":[{"given":"Ronald T.","family":"Gansevoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Minini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curie","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mrug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.M.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York P.C.","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Modur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Antonshchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2022.10.016_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2022.10.016_bib2","first-page":"1356","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2022.10.016_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","article-title":"Autosomal dominant polycystic kidney disease","volume":"329","author":"Gabow","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2022.10.016_bib4","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2022.10.016_bib5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ajpath.2014.03.007","article-title":"Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease","volume":"184","author":"Galarreta","year":"2014","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1053\/j.ajkd.2022.10.016_bib6","first-page":"667","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev\u00a0Nephrol"},{"key":"10.1053\/j.ajkd.2022.10.016_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJNRD.S136359","article-title":"Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment","volume":"11","author":"Barnawi","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1053\/j.ajkd.2022.10.016_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109526","article-title":"Glycosphingolipid metabolism and polycystic kidney disease","volume":"69","author":"Natoli","year":"2020","journal-title":"Cell Signal"},{"issue":"6","key":"10.1053\/j.ajkd.2022.10.016_bib11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0022-2275(20)39163-X","article-title":"Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease","volume":"37","author":"Chatterjee","year":"1996","journal-title":"J\u00a0Lipid Res"},{"issue":"9","key":"10.1053\/j.ajkd.2022.10.016_bib12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-2275(20)41159-9","article-title":"Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk\/cpk) mouse","volume":"35","author":"Deshmukh","year":"1994","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1053\/j.ajkd.2022.10.016_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1053\/j.ajkd.2022.10.016_bib14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat Med"},{"issue":"10","key":"10.1053\/j.ajkd.2022.10.016_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100538","article-title":"The STAGED-PKD two-stage adaptive study with a patient enrichment strategy and treatment effect modeling for improved study design efficiency in patients with ADPKD","volume":"4","author":"Perrone","year":"2022","journal-title":"Kidney Med"},{"issue":"1","key":"10.1053\/j.ajkd.2022.10.016_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2022.10.016_bib18","article-title":"Historical control analysis demonstrates superior reduction of plasma globotriaosylcermaide by vneglustat compared with placebo or agalsidase beta in classic Fabry disease patients","volume":"35","author":"Germain","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2022.10.016_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"issue":"4","key":"10.1053\/j.ajkd.2022.10.016_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfx188","article-title":"Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial","volume":"33","author":"Cornec-Le Gall","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"10.1053\/j.ajkd.2022.10.016_bib21","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2022.10.016_bib22","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2022.10.016_bib23","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ajkd.2022.10.016_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2022.10.016_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2022.10.016_bib26","article-title":"Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease","volume":"11","author":"Nicholson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1053\/j.ajkd.2022.10.016_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/ijms20020411","article-title":"Ceramide and regulation of vascular tone","volume":"20","author":"Cogolludo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1053\/j.ajkd.2022.10.016_bib28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622010794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622010794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:49:04Z","timestamp":1759463344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622010794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0272638622010794"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2\/3 Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}